BackgroundInterferon induced transmembrane protein 3 (IFITM3) plays an important role in the tumorigenesis and progression of multiple cancers. This study investigated the expression and function of IFITM3 in human lung adenocarcinoma.MethodsFifty human lung adenocarcinoma tissues were collected. IFITM3 expression was assessed by immunohistochemical staining. The clinicopathologic characteristics of all patients were analyzed.Results IFITM3 was mainly detected in the cytoplasm of advanced cancer tissues and its expression was correlated with tumor malignancy grade. Knockdown of IFITM3 in vitro markedly inhibited the proliferation and invasion of lung adenocarcinoma cells.Conclusion IFITM3 represents a potential therapeutic target for the treatment of lung adenocarcinoma.

Introduction: This pre-specified subgroup analysis evaluated the efficacy and safety of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler (BGF MDI) triple therapy versus corresponding dual therapies in the China subgroup of the phase III, doubleblind KRONOS study in patients with moderate to very severe chronic obstructive pulmonary disease (COPD). Methods: Patients were randomized 2:2:1:1 to BGF MDI 320/18/9.6 lg, glycopyrrolate/formoterol fumarate (GFF) MDI 18/9.6 lg, budesonide/formoterol fumarate (BFF) MDI 320/9.6 lg, or budesonide/formoterol fumarate dry powder inhaler (BUD/FORM DPI) 400/12 lg twice daily for 24 weeks. The primary endpoint was change from baseline in morning pre-dose trough forced expiratory volume in 1 s (FEV 1) over weeks 12-24. Secondary endpoints included symptoms, health-related quality of life, and safety. Rate of moderate/severe COPD exacerbations was an additional efficacy endpoint.

No abstract